In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: West Pharmaceutical shares trade 42% above their $189.81 fair value, indicating potential overvaluation relative to intrinsic metrics like DCF ($93.05) and EV/EBITDA ($174.53). Despite excellent financial health and profitability, growth scores are low, and Monte Carlo analysis shows 100% downside risk below current price. High valuation volatility and disparity between analyst targets and fundamental models suggest elevated investment risk.